News
OrbusNeich obtains additional preliminary injunction against Boston Scientific in Germany
OrbusNeich Medical Inc. and its subsidiary, OrbusNeich Medical GmbH (collectively, "OrbusNeich"), today announced that the Dusseldorf Regional Court has issued a second preliminary injunction against...
News
Creabilis Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327
Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline results of its Phase 2b trial with its...
News
Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets
The limited efficacy and negative side-effects associated with current therapeutics for Hepatitis B and C are highlighting the urgent need for new, improved alternatives. Combination...
News
Accordia Global Health Foundation Names David Greeley as President and CEO
The Board of Directors of Accordia Global Health Foundation voted unanimously to appoint David Greeley as its new President and CEO. David brings with him...
News
Academy of Nutrition and Dietetics Members Evaluate Existing Evidence on Umami in Foods
The addition of umami compounds or foods rich in umami, allows for reductions in sodium content of foods without sacrificing taste, liking and pleasantness, according...
News
First State Worldwide to Establish Statutory Regulations for Sepsis Management
The Rory Staunton Foundation and Global Sepsis Alliance today announced that they will unite to fight against sepsis, which claims 8-9 million lives annually. They...
News
NW Bio’s Phase III Trial With DCVax®-L For Brain Cancer “Adopted” As A National Priority Trial In UK
Northwest Biotherapeutics , a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Company's Phase III clinical trial for...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.